Lactoferrin-derived Peptides (LfcinB)
Also known as: Lactoferricin B, LfcinB, Lactoferrin-derived antimicrobial peptide
Antimicrobial peptides derived from lactoferrin that modulate innate immunity and have direct bactericidal activity.
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Localized redness, swelling, or tenderness at the injection site typically resolves within 24-48 hours. Minimize by allowing the solution to reach room temperature before injection, rotating sites systematically, and using proper injection technique. Apply ice for 10 minutes if discomfort persists.
Low-grade fever (37.5-38.5°C) or mild chills may occur 2-6 hours after injection due to immune activation and cytokine release. Typically self-resolving within 12-24 hours. Monitor temperature; contact healthcare provider if fever exceeds 38.5°C or persists beyond 24 hours.
May occur if the peptide reaches the GI tract or triggers systemic immune activation. Usually resolves within 24-48 hours. Ensure adequate hydration and take with food if tolerated. Discontinue if symptoms persist or worsen.
Mild to moderate headache may occur in the first 24 hours post-injection, likely related to immune activation and cytokine release. Manage with over-the-counter analgesics (acetaminophen or ibuprofen) and adequate hydration.
Repeated injections at the same site can cause localized fat loss (lipoatrophy) or fat thickening (lipohypertrophy). Prevent by rotating injection sites systematically with each dose, maintaining at least 1 inch between previous injection points, and keeping detailed injection logs.
Hypersensitivity to the peptide or excipients may manifest as localized or generalized rash, hives, or facial/throat swelling. Discontinue immediately and seek medical evaluation. Have antihistamines available. Anaphylaxis is extremely rare but requires emergency medical attention.
Excessive immune activation may cause elevated CRP, ESR, or white blood cell count. Monitor inflammatory markers during clinical trials. Reduce dose or increase interval between injections if markers become significantly elevated. Consult healthcare provider before continuing.
Bacterial or fungal infection may occur if sterile technique is not maintained. Signs include increasing redness, warmth, swelling, pus, or systemic fever. Seek immediate medical evaluation. Ensure all equipment is sterile and injection sites are cleaned thoroughly before each injection.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 50-200 mcg |
| Frequency | 1-2x daily |
| Timing | Morning and evening, or as directed by research protocol |
| Route | Subcutaneous |
Dosage varies significantly by study protocol and route of administration. For research purposes only. Subcutaneous administration is most common in clinical trials; some protocols use intranasal or oral delivery. Start at lower end and titrate based on immune response markers and tolerability.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 3102 Da |
| Half-life | Approximately 30-60 minutes in serum (varies by route and formulation); longer retention at mucosal surfaces |
| Sequence | FKCRRWQWRMKKLGAPSITCVRRAF |
Lactoferricin B (LfcinB) is a cationic antimicrobial peptide derived from the N-terminal region of lactoferrin that exerts dual mechanisms: direct bactericidal activity through disruption of bacterial cell membranes and iron sequestration, and immunomodulatory effects through activation of innate immune cells including neutrophils, macrophages, and dendritic cells. The peptide enhances antimicrobial peptide production, promotes inflammatory cytokine release, and supports mucosal barrier function, making it effective against both gram-positive and gram-negative pathogens.
Direct Antimicrobial Activity
LfcinB disrupts bacterial cell membranes through electrostatic interactions with negatively charged lipopolysaccharides and phospholipids. The peptide also sequesters iron (Fe3+), depriving bacteria of this essential cofactor for growth and virulence factor production. This dual mechanism provides broad-spectrum activity against Staphylococcus aureus, Escherichia coli, Helicobacter pylori, and other pathogens.
Innate Immune Cell Activation
LfcinB activates neutrophils, macrophages, and dendritic cells through pattern recognition receptors and TLR signaling, enhancing phagocytic capacity, oxidative burst, and antimicrobial peptide production. This amplifies the endogenous antimicrobial response and promotes clearance of pathogens.
Inflammatory Cytokine Modulation
The peptide stimulates production of pro-inflammatory cytokines (TNF-α, IL-6, IL-8) and chemokines that recruit immune cells to sites of infection or inflammation. It also promotes IL-10 and TGF-β production, supporting resolution of inflammation and tissue repair.
Mucosal Barrier Support
LfcinB enhances tight junction protein expression and mucin production in intestinal and respiratory epithelial cells, strengthening the mucosal barrier against pathogenic colonization and translocation.
- LfcinB is a 25-amino acid cationic peptide with net positive charge, enabling electrostatic binding to bacterial membranes
- The peptide demonstrates activity against antibiotic-resistant pathogens including MRSA and multidrug-resistant gram-negative bacteria
- Iron sequestration by LfcinB reduces bacterial virulence and biofilm formation independent of direct membrane disruption
- Immune activation by LfcinB is mediated through TLR2, TLR4, and formyl peptide receptors on innate immune cells
- The peptide crosses mucosal barriers and reaches systemic circulation when administered intranasally or orally, though bioavailability is limited by proteolytic degradation
- LfcinB synergizes with conventional antibiotics and other antimicrobial peptides, offering potential for combination therapy
Track your Lactoferrin-derived Peptides (LfcinB) research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Lactoferrin-derived Peptides (LfcinB) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.